Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Emil_D._Kakkis
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:CUSIP |
90400D108
|
| gptkbp:focus |
rare and ultra-rare genetic diseases
|
| gptkbp:foundedYear |
2010
|
| gptkbp:hasCompany |
gptkb:Ultragenyx_Pharmaceutical_Inc.
|
| gptkbp:headquartersLocation |
gptkb:Novato,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ: RARE
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US90400D1081
|
| gptkbp:market |
gptkb:NASDAQ_Global_Select_Market
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
RARE
|
| gptkbp:website |
https://www.ultragenyx.com/
|
| gptkbp:bfsParent |
gptkb:Ultragenyx
|
| gptkbp:bfsLayer |
7
|